Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment

INTRODUCTION: Immediate-release sodium oxybate (SXB) has been Food and Drug Administration (FDA)-approved to treat narcolepsy since 2002; in 2020, a mixed-salt oxybates formulation was also approved. Both are taken at bedtime with a second dose taken 2.5–4 h later. A third oxybate option, an investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Morse, Anne Marie, Krahn, Lois, Flygare, Julie, Kushida, Clete, Thorpy, Michael J., Athavale, Amod, Gudeman, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272269/
https://www.ncbi.nlm.nih.gov/pubmed/37243863
http://dx.doi.org/10.1007/s12325-023-02532-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272269/
https://www.ncbi.nlm.nih.gov/pubmed/37243863
http://dx.doi.org/10.1007/s12325-023-02532-y

Ejemplares similares